Exocrine Pancreatic Insufficiency

Exocrine Pancreatic Insufficiency

Global Exocrine Pancreatic Insufficiency Market to Reach US$8.7 Billion by 2030

The global market for Exocrine Pancreatic Insufficiency estimated at US$5.9 Billion in the year 2023, is expected to reach US$8.7 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2023-2030. Exocrine Pancreatic Insufficiency Therapeutics, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Exocrine Pancreatic Insufficiency Diagnostics segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 5.3% CAGR

The Exocrine Pancreatic Insufficiency market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Exocrine Pancreatic Insufficiency Market - Key Trends & Drivers Summarized

What Is Exocrine Pancreatic Insufficiency and How Is It Managed?
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the pancreas’ inability to produce or transport enough digestive enzymes, leading to malabsorption and digestive issues. It is commonly associated with conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer. Managing EPI typically involves enzyme replacement therapy (ERT), where patients take pancreatic enzyme products (PEPs) to aid digestion and improve nutrient absorption. The growing awareness and diagnosis of EPI, combined with the availability of effective enzyme replacement therapies, are driving the demand for treatments and diagnostic solutions in the market.

How Are Advancements in Diagnostic Techniques and Enzyme Formulations Impacting the Market?
Technological advancements in diagnostics and enzyme formulations have significantly impacted the exocrine pancreatic insufficiency market. Innovations in non-invasive diagnostic techniques, such as fecal elastase tests and advanced imaging technologies, enable early and accurate detection of EPI, leading to timely intervention. Moreover, pharmaceutical companies are developing advanced pancreatic enzyme formulations, including enteric-coated tablets and microencapsulated enzymes, which improve the efficacy of treatment and enhance patient compliance. These technological advancements are crucial in providing better therapeutic outcomes for patients, ensuring that treatments are both effective and convenient.

Are Regulatory Approvals and Healthcare Accessibility Influencing Market Growth?
Regulatory approvals and the accessibility of healthcare significantly influence the EPI market. The approval of new enzyme replacement therapies by regulatory bodies like the FDA and EMA has expanded treatment options, ensuring that patients have access to safe and effective therapies. Additionally, the rise of healthcare infrastructure and accessibility, especially in emerging markets, supports the diagnosis and treatment of EPI. Increased awareness campaigns by healthcare providers and pharmaceutical companies also contribute to better patient education, encouraging individuals to seek diagnosis and treatment for symptoms of EPI. These trends underscore the importance of healthcare policies and regulatory frameworks in shaping the availability and adoption of EPI therapies globally.

What Is Driving the Growth of the Exocrine Pancreatic Insufficiency Market?
The growth in the exocrine pancreatic insufficiency market is driven by several factors, including the rising prevalence of conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer, which are primary causes of EPI. The development of advanced pancreatic enzyme replacement therapies, designed to enhance treatment efficacy and patient compliance, further propels the market. Additionally, technological advancements in diagnostic methods facilitate early and accurate detection, encouraging timely intervention and increasing the demand for enzyme therapies. Regulatory approvals and healthcare initiatives that improve access to EPI diagnosis and treatment also play a crucial role in market growth, ensuring that patients worldwide have access to effective management solutions for exocrine pancreatic insufficiency.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Allergan PLC
• Anthera Pharmaceuticals, Inc.
• AzurRx BioPharma, Inc.
• Cilian AG
• Digestive Care, Inc.
• Janssen Pharmaceuticals, Inc.
• Nordmark Arzneimittel GmbH & Co. KG

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.